Indoco Remedies Ltd., incorporated in the year 1947, is a Small Cap company (having a market cap of Rs 3507.24 Crore) operating in Pharmace...

Promoters held 58.69 per cent stake in the company as of 31-Mar-2022, while FIIs owned 1.15 per cent, DIIs 18.28 per cent.

Shares of Indoco Remedies have delivered over more than 100 per cent return in the last one year. The pharma counter has gained about 12 pe...

Aditi Kare Panandikar, Managing Director - Indoco Remedies said: "This is Indoco's first own label product in Europe. Germany is totally te...

In a BSE filing, Indoco Remedies announced receipt of approval for its abbreviated new drug application (ANDA) for Olanzapine Tablets USP i...

The inspection by UK health regulator, MHRA were held from September 16-20, 2019 and resulted in 2 observations, Indoco Remedies said in a ...

With this development, the company's operations in Europe will now take off on a fast-track, Indoco Remedies MD Aditi Panandikar said.

"We are happy to receive the EIR in less than two months from the date of inspection," Indoco Remedies MD Aditi Kare Panandikar said.

Indoco Remedies is a smallcap company, operating in pharmaceuticals and health care sector.

The facility was inspected by the USFDA in January 2019.

In the Nifty50 index, 14 stocks were trading in the green, while 35 stocks were in the red.

Hold Indoco Remedies Ltd. at a price target of Rs 190.0 .

Shares of Indoco Remedies were trading at Rs 191, down 0.49 per cent on BSE.

The United States Food and Drug Administration (USFDA) inspected the company's Goa Plant II from August 31, 2016 to September 4, 2016, Indo...

"Indoco Remedies is a 'BUY' call with a target of Rs 311 and a stop loss of Rs 278."

Indoco Remedies, a Rs 215-crore Mumbai-based pharmaceutical company, has acquired La NovaChem’s active pharmaceutical ingredient (API) manu...

Indoco Remedies Ltd, a manufacturer and distributor of pharmaceutical products and services, on Tuesday said it has acquired a 100 per cent...